公开(公告)号：UA95939C2

公开(公告)日：2011-09-26

申请号：UAA200809945

申请日：2007-01-30

Applicant: UCB PHARMA SA

Inventor： HUTCHINGS MARTIN CLIVE ,  ARCHIBALD SARAH CATHERINE ,  BROOKINGS DANIEL CHRISTOPHER ,  DAVIS JEREMY MARTIN ,  JOHNSON JAMES ANDREW ,  LANGHAM BARRY JOHN ,  NEUSS JUDI CHARLOTTE

IPC: C07D495/04 ,  A61K31/4365

Abstract: Серияпроизводныхтиено[2,3-b]пиридина, замещенныхв положении 2 замещенныманилиновымфрагментом, селективныхингибиторовферментовМЕК (МАРКК) человека, которые, соответственно, пригодныдляпримененияв медицине, напримердлялечениявоспалительных, аутоиммунных, сердечно-сосудистых, пролиферативныхсостояний (втомчислеонкологических) исостояний, которыесопровождаютсяболью.

公开(公告)号：ZA200807447B

公开(公告)日：2009-11-25

申请号：ZA200807447

申请日：2007-01-30

Applicant: UCB PHARMA SA

Inventor： HUTCHINGS MARTIN CLIVE ,  ARCHIBALD SARAH CATHERINE ,  BROOKINGS DANIEL CHRISTOPHER ,  DAVIS JEREMY MARTIN ,  JOHNSON JAMES ANDREW ,  LANGHAM BARRY JOHN ,  NEUSS JUDI CHARLOTTE

IPC: A61K20100101 ,  C07D20100101

Abstract: Novel processes for the preparation of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety and intermediates thereto are provided. The compounds prepared by the present processes may be useful, for example, as selective inhibitors of human MEK (MAPKK) enzymes, and are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. The present processes may offer improved yields, chemical or stereochemical purity, ease of preparation and/or isolation of intermediates and final product, and more industrially useful reaction conditions and workability.

公开(公告)号：AU2003252990B2

公开(公告)日：2009-07-09

申请号：AU2003252990

申请日：2003-08-11

Applicant: UCB PHARMA SA

Inventor： BROOKINGS DANIEL CHRISTOPHER ,  LANGHAM BARRY JOHN ,  DAVIS JEREMY MARTIN

IPC: C07D495/04 ,  A61K31/4365 ,  A61P1/02 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P3/10 ,  A61P7/02 ,  A61P7/04 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P19/02 ,  A61P19/06 ,  A61P19/08 ,  A61P19/10 ,  A61P21/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/16 ,  A61P25/28 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/14 ,  A61P31/16 ,  A61P31/18 ,  A61P31/20 ,  A61P31/22 ,  A61P33/06 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  A61P43/00

Abstract: A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 6-oxo-6,7-dihydrothieno[2,3-b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.

公开(公告)号：AU2003253087B2

公开(公告)日：2008-10-16

申请号：AU2003253087

申请日：2003-06-20

Applicant: UCB PHARMA SA

Inventor： DAVIS JEREMY MARTIN ,  BROOKINGS DANIEL CHRISTOPHER ,  LANGHAM BARRY JOHN

IPC: C07D495/04 ,  A61K31/4743 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/02 ,  A61P7/04 ,  A61P7/06 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P21/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/12 ,  A61P31/16 ,  A61P31/22 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00

Abstract: Bicyclic heteroaromatic derivatives of formula (1) are described: F(1) where: the dashed line joining A and C(Ra) is present and represents a bond and A is a —N═ atom or a —C(Rb)═ group, or the dashed line is absent and A is a —N(Rb)—, or —C(Rb)(Rc)— group; X is an —O—, —S— or substituted nitrogen atom or a —S(O)—, —S(O2)— or —NH-group; Y is a nitrogen or substituted carbon atom or a —CH═ group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the remaining substituents are defined in the specification. The compounds are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders.

公开(公告)号：AU2004249495A1

公开(公告)日：2004-12-29

申请号：AU2004249495

申请日：2004-06-18

Applicant: UCB PHARMA SA

Inventor： DAVIS JEREMY MARTIN ,  BROOKINGS DANIEL CHRISTOPHER ,  LANGHAM BARRY JOHN

IPC: C07D495/04 ,  A61K31/4365 ,  A61P29/00

Abstract: A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-1-yl or related moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.